Radiofrequency Fields in Neonatology: Exposure and Impact on the Nervous System
Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Feb 20, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking into the exposure of preterm newborns to radiofrequency (RF) fields, which are low levels of electromagnetic energy that can come from devices like cell phones and wireless equipment. Researchers want to see how this exposure might affect the nervous system of these infants while they are in the neonatal intensive care units (NICUs). They will measure the RF levels that each baby is exposed to during their first week of life and examine how it relates to their brain and heart activity.
To participate in this study, babies need to be born preterm, specifically between 26 and 34 weeks of gestation. Unfortunately, infants who have certain medical issues, like infections or serious health problems, won't be eligible. Throughout the study, the researchers will continuously monitor the babies' health and then assess their brain and heart activity at the end of the week. This research aims to gather important information that could help understand the effects of RF exposure in different NICU environments across France.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • preterm newborns born between 26-34 weeks of gestational age
- Exclusion Criteria:
- • infants infected,
- • suffering from neurological disorders,
- • serious heart, respiratory, digestive or metabolic diseases;
- • infants born from mothers aged less than 18 years old or deprived of their parental rights
About Centre Hospitalier Universitaire, Amiens
The Centre Hospitalier Universitaire (CHU) Amiens is a leading academic medical center in France dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on multidisciplinary collaboration, CHU Amiens integrates patient care, education, and research to enhance treatment outcomes and improve patient quality of life. The institution is committed to ethical standards and regulatory compliance in its clinical research endeavors, aiming to contribute significantly to the medical community and the development of new therapeutic approaches. By fostering partnerships with various stakeholders, CHU Amiens strives to translate scientific discoveries into practical applications that benefit patients and healthcare systems alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amiens, Picardie, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported